RBC Maintains Outperform on Xylem After Mixed Q4 Results; $176 Target Intact
RBC Capital reiterated an Outperform rating and a $176.00 price target on Xylem (NYSE:XYL) following the company’s fourth-quarter 2025 results. The firm highlighted a modest operating beat, above-guidance organic sales growth and exceptionally strong free cash flow conversion, while noting mixed margin performance across segments and cautious guida…